Page 13 - Coronavirus Vaccine

Data story: India adds 2,141 new Covid cases; active tally at 25,510

India has added 15,198 cases in the past 7 days

Updated On : 20 Oct 2022 | 9:35 AM IST

Winter is coming: New Covid-19 variants prompt alert for illness season

Health minister Mansukh Mandaviya holds review meeting as experts call for continued vigil

Updated On : 19 Oct 2022 | 12:56 PM IST

Omicron sub-variant BF.7 behind China surge sparks concerns in India

Amid rising concerns around Omicron sub-variant that caused surge in China, the network of government scientists and labs responsible for genome-sequencing strains of Covid-19 virus are likely to meet

Updated On : 18 Oct 2022 | 11:25 AM IST

Data story: India adds 1,542 new Covid cases; death toll at 528,913

India has added 16,036 cases in the past 7 days

Updated On : 18 Oct 2022 | 9:06 AM IST

India's Covid-19 vaccination not over yet, govt still has 30 mn in stock

With already more than 200 Cr vaccine (first, second and precautionary) doses administered across the country so far

Updated On : 17 Oct 2022 | 9:53 AM IST

Govt not to procure fresh Covid vaccines; surrenders Rs 4k cr from budget

The government's Covid vaccination programme is in its final leg with the Health Ministry deciding against procuring more vaccines as of now and surrendering Rs 4,237 crore, or nearly 85 per cent of the 2022-23 budget allocation for inoculation purposes, to the Finance Ministry. Official sources told PTI that more than 1.8 crore doses are still available with the governments at the Centre and in states and the stock is sufficient to continue the vaccination drive for around six months, given the low uptake of vaccines among people due to declining Covid case burden. Even if the government's stock gets exhausted, Covid vaccines will be available in the market. "Any decision on whether to procure Covid vaccine doses through the government channel or get (fresh) budget allocations for the purpose after six months will depend on the coronavirus situation prevailing in the country at that time," an official source told PTI. As part of the nationwide vaccination drive which began on Janu

Updated On : 16 Oct 2022 | 4:57 PM IST

Data story: India adds 2,430 new cases of Covid; active tally at 26,618

India has added 17,110 cases in the past 7 days

Updated On : 15 Oct 2022 | 9:46 AM IST

Data story: India adds 2,786 new Covid cases; active tally rises to 26,509

India has added 16,856 cases in the past 7 days

Updated On : 14 Oct 2022 | 4:53 PM IST

US FDA authorises updated Moderna, Pfizer Covid boosters for children

The US Food and Drug Administration (FDA) has authorised the updated Moderna and Pfizer-BioNTech Covid-19 booster shots for children as young as five

Updated On : 13 Oct 2022 | 11:33 AM IST

Temporary Covid-19 centres getting dismantled amid signs pandemic is ending

About 92% of cases in India are said to be having mild disease. In only 5.8% of cases oxygen therapy is required, intensive care in only 1.7% cases

Updated On : 12 Oct 2022 | 2:30 PM IST

Data story: India logs 2,139 new Covid cases; death toll reaches 528,835

India has added 16,599 cases in the past 7 days

Updated On : 12 Oct 2022 | 10:17 AM IST

India's first Covid cure Vincov-19 completes second phase clinical trial

Completes phase 2 trials successfully on 200 patients

Updated On : 11 Oct 2022 | 11:16 PM IST

AstraZeneca's nasal Covid vaccine not as effective as expected: Study

AstraZeneca's intranasally-administered vaccine against COVID-19 did not perform as expected in a small study published on Tuesday, suggesting there are likely to be challenges in making nasal sprays a reliable option. The findings from a Phase 1 clinical trial, published in the journal eBioMedicine, show mucosal antibody responses were generated in a minority of participants. Systemic immune responses, which involves many other immune cells, to intranasal vaccination were also weaker compared with intramuscular vaccination, the researchers said. The study was performed in collaboration with the University of Oxford and used the same vaccine based on the ChAdOx1 adenovirus vector, as is already licensed for use by injection. The ChAdOx1 vector used in the vaccine is a weakened version of a common cold virus (adenovirus) that has been genetically modified so it is impossible for it to replicate in humans. The latest study is thought to be the first to have published data from ...